Eli Lilly to double Mounjaro production

Analysts have returned from a visit to the drugmaker’s Indianapolis headquarters, reporting that Lilly is facing a number of headwinds, one of which will be warded off by doubling the firm’s production capacity for Mounjaro.

In an attempt to mitigate future financial challenges, Eli Lilly will double the production of its newest and highly sought-after type 2 diabetes drug, Mounjaro, reports industry media Endpoints News.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs